Terms: = Liver cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Staging
17 results:
1. Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region.
Waked I; Alsammany S; Tirmazy SH; Rasul K; Bani-Issa J; Abdel-Razek W; Omar A; Shafik A; Eid S; Abdelaal A; Hosni A; Esmat G
Liver Int; 2023 Oct; 43(10):2062-2077. PubMed ID: 37553777
[TBL] [Abstract] [Full Text] [Related]
2. [A Case of Multiple Brain Metastases after Surgery for Lung cancer Successfully Treated with Osimertinib].
Takeuchi K; Hayakawa N; Ouchi M
Gan To Kagaku Ryoho; 2023 May; 50(5):631-633. PubMed ID: 37218327
[TBL] [Abstract] [Full Text] [Related]
3. A Macrophage Differentiation-Mediated Gene: DDX20 as a Molecular Biomarker Encompassing the Tumor Microenvironment, Disease staging, and Prognoses in Hepatocellular Carcinoma.
Yang Y; Yang M; Pang H; Qiu Y; Sun T; Wang T; Shen S; Wang W
Oxid Med Cell Longev; 2022; 2022():9971776. PubMed ID: 36246406
[TBL] [Abstract] [Full Text] [Related]
4. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
5. Protective effect of the RNA-binding protein RBM10 in hepatocellular carcinoma.
Zhao Z; Li J; Shen F
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6005-6013. PubMed ID: 32572914
[TBL] [Abstract] [Full Text] [Related]
6. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract] [Full Text] [Related]
7. Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case report.
Song P; Yang J; Li X; Huang H; Guo X; Zhou G; Xu X; Cai Y; Zhu M; Wang P; Zhao S; Zhang D
Medicine (Baltimore); 2017 Sep; 96(39):e8122. PubMed ID: 28953642
[TBL] [Abstract] [Full Text] [Related]
8. Recent insights in the therapeutic management of patients with gastric cancer.
de Mestier L; Lardière-Deguelte S; Volet J; Kianmanesh R; Bouché O
Dig Liver Dis; 2016 Sep; 48(9):984-94. PubMed ID: 27156069
[TBL] [Abstract] [Full Text] [Related]
9. Biologic therapies in colorectal cancer: indications and contraindications.
Fakih M
Am Soc Clin Oncol Educ Book; 2015; ():e197-206. PubMed ID: 25993173
[TBL] [Abstract] [Full Text] [Related]
10. Distinct features of distant metastasis and lymph node stage in lung adenocarcinoma patients with epidermal growth factor receptor gene mutations.
Enomoto Y; Takada K; Hagiwara E; Kojima E
Respir Investig; 2013 Sep; 51(3):153-7. PubMed ID: 23978641
[TBL] [Abstract] [Full Text] [Related]
11. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline.
Donat SM; Diaz M; Bishoff JT; Coleman JA; Dahm P; Derweesh IH; Herrell SD; Hilton S; Jonasch E; Lin DW; Reuter VE; Chang SS
J Urol; 2013 Aug; 190(2):407-16. PubMed ID: 23665399
[TBL] [Abstract] [Full Text] [Related]
12. Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination.
Viana Lde S; Affonso RJ; Silva SR; Denadai MV; Matos D; Salinas de Souza C; Waisberg J
Oncology; 2013; 84(2):81-91. PubMed ID: 23128103
[TBL] [Abstract] [Full Text] [Related]
13. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Lee YH; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Huo TI; Lee SD
J Gastroenterol Hepatol; 2012 Oct; 27(10):1581-8. PubMed ID: 22497632
[TBL] [Abstract] [Full Text] [Related]
14. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract] [Full Text] [Related]
15. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
[TBL] [Abstract] [Full Text] [Related]
16. [Correlations of c-erb-B2, egfr, and TGF-alpha expression to recurrence of Dukes'A and B colorectal carcinoma].
Liang JL; Wan DS; Pan ZZ; Zhou ZW
Ai Zheng; 2007 Jun; 26(6):647-51. PubMed ID: 17562274
[TBL] [Abstract] [Full Text] [Related]
17. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel.
Barozzi C; Ravaioli M; D'Errico A; Grazi GL; Poggioli G; Cavrini G; Mazziotti A; Grigioni WF
Cancer; 2002 Feb; 94(3):647-57. PubMed ID: 11857296
[TBL] [Abstract] [Full Text] [Related]
